EichorEICHOR
Location: St John S Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near St John S

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Phase 3 · Princess Maxima Center for Pediatric Oncology · NCT05327894PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
Phase 2 · Boehringer Ingelheim · NCT07355296A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer
Phase 3 · UroGen Pharma Ltd. · NCT06774131A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants Wit
Phase 3 · Merck Sharp & Dohme LLC · NCT06077760Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Phase 3 · Gilead Sciences · NCT06051617Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesop
Phase 3 · Daiichi Sankyo · NCT06731478A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Phase 2 · Merck Sharp & Dohme LLC · NCT07133633A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Phase 3 · Dimerix Bioscience Pty Ltd · NCT05183646A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3 · Daiichi Sankyo · NCT06203210Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Phase 3 · Revolution Medicines, Inc. · NCT06881784Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in
Phase 3 · Merck Sharp & Dohme LLC · NCT03486873A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary
Phase 2 · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis P · NCT05128825A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-108
Phase 3 · Merck Sharp & Dohme LLC · NCT06997497A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurre
Phase 3 · Janssen Research & Development, LLC · NCT07276399A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Phase 3 · Mats Heyman · NCT04307576High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Phase 3 · St. Anna Kinderkrebsforschung · NCT01704716Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Ce
Phase 3 · Merck Sharp & Dohme LLC · NCT06422143C-Brace Prospective Registry
Phase N/A · Otto Bock Healthcare Products GmbH · NCT04640584A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 · Merck Sharp & Dohme LLC · NCT07060807A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leuke
Phase 3 · Janssen Research & Development, LLC · NCT06852222Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
NA · AtaCor Medical, Inc. · NCT07324031A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembroliz
Phase 2/Phase 3 · BioNTech SE · NCT04534205LANDMARK Trial: a Randomised Controlled Trial of Myval THV
NA · Meril Life Sciences Pvt. Ltd. · NCT04275726MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Ha
Phase 3 · Pfizer · NCT06152575Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for L
Phase 2/Phase 3 · BioNTech SE · NCT06712316Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma
Phase 2 · Chiesi Farmaceutici S.p.A. · NCT07301736Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Phase N/A · Boston Scientific Corporation · NCT02071134A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Al
Phase 3 · Merck Sharp & Dohme LLC · NCT06952504Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Phase 2 · Merck Sharp & Dohme LLC · NCT04728893Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Phase 2 · Taiho Oncology, Inc. · NCT05727176
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.